Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00283
|
|||||
Drug Name |
Dopamine
|
|||||
Synonyms |
(3H)-Dopamine; 1,2-Benzenediol, 4-(2-aminoethyl)-(9CI); 1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride; 1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium; 153C5321-5FEE-4B0B-8925-F388F0EEEBD1; 2-(3,4-dihydroxyphenyl)ethylamine; 2-benzenediol; 3,4-Dihydroxyphenethylamine hydrochloride; 3,4-Dihydroxyphenylethylamine; 3,4-dihydroxyphenethylamine; 3-Hydroxtyramine; 3-Hydroxytyramine; 3-Hydroxytyramine Hydrobromide; 3-Hydroxytyramine hydrochloride; 4-(2-Aminoethyl)-1; 4-(2-Aminoethyl)-1,2-benzenediol; 4-(2-Aminoethyl)-1,2-bezenediol; 4-(2-Aminoethyl)benzene-1,2-diol; 4-(2-Aminoethyl)catechol; 4-(2-Aminoethyl)pyrocatechol; 4-(2-Aminoethyl)pyrocatechol hydrochloride; 4-(2-aminoethyl)-pyrocatechol; A-(3,4-Dihydroxyphenyl)-b-aminoethane; ASL 279; Alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane; Beta-(3,4-Dihydroxyphenyl)ethylamine hydrochloride; Dopamin; Dopamina; Dopamina [INN-Spanish]; Dopamine (INN); Dopamine (USAN)(*hydrochloride*); Dopamine [INN:BAN]; Dopaminum; Dopaminum [INN-Latin]; Dophamine; Hydroxytyramin; Hydroxytyramine; IP 498; Intropin; Intropin [*hydrochloride*]; KW-3-060; L-DOPAMINE; LDP; M-Hydroxytyramine hydrochloride; Medopa (TN); Oxytyramine; Pyrocatechol, 4-(2-aminoethyl)-(8CI); Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride; Revimine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Parkinson's Disease [ICD11: 8A00.0] | Approved | [1] | |||
Therapeutic Class |
Cardiotonic Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C8H11NO2
|
|||||
Canonical SMILES |
C1=CC(=C(C=C1CCN)O)O
|
|||||
InChI |
InChI=1S/C8H11NO2/c9-4-3-6-1-2-7(10)8(11)5-6/h1-2,5,10-11H,3-4,9H2
|
|||||
InChIKey |
VYFYYTLLBUKUHU-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 51-61-6
|
|||||
Pharmaceutical Properties | Molecular Weight | 153.18 | Topological Polar Surface Area | 66.5 | ||
Heavy Atom Count | 11 | Rotatable Bond Count | 2 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 3 | |||
XLogP |
-1
|
|||||
PubChem CID | ||||||
PubChem SID |
11111282
, 11335955
, 11361194
, 11363906
, 11364800
, 11364894
, 11366468
, 11367362
, 11367456
, 11369030
, 11369924
, 11370018
, 11371252
, 11372964
, 11373057
, 11374268
, 11375524
, 11375618
, 11377192
, 11378091
, 11378187
, 11462166
, 11484941
, 11488839
, 11490222
, 11492340
, 11494826
, 11534314
, 15170929
, 24439043
, 26612791
, 26719173
, 26750067
, 26753786
, 26753787
, 3133522
, 37024415
, 4396596
, 444583
, 46506043
, 47213204
, 6517
, 7888623
, 794678
, 7979122
, 8026221
, 8145174
, 8150742
, 840958
, 841083
|
|||||
ChEBI ID |
ChEBI:18243
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | DAT1 | Transporter Info | Sodium-dependent dopamine transporter | Substrate | [2] | |
OCT-1 | Transporter Info | Organic cation transporter 1 | Substrate | [3] | ||
OCT-2 | Transporter Info | Organic cation transporter 2 | Substrate | [4] | ||
SV2C | Transporter Info | Synaptic vesicle glycoprotein 2C | Substrate | [5] | ||
VMAT1 | Transporter Info | Vesicular amine transporter 1 | Substrate | [6] | ||
VMAT2 | Transporter Info | Vesicular amine transporter 2 | Substrate | [6] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | OCT-2 | Transporter Info | Km = 330 microM | Human embryonic kidney cells (HEK293)-OCT2 | [7] | |
OCT-2 | Transporter Info | Km = 1400 microM | Human embryonic kidney cells (HEK293)-OCT2 | [4] | ||
OCT-2 | Transporter Info | Km = 390 microM | Oocytes-OCT2 | [7] | ||
References | ||||||
1 | Dopamine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236. | |||||
3 | Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53. | |||||
4 | Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52. | |||||
5 | Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262. | |||||
6 | SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72. | |||||
7 | Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol. 1998 Aug;54(2):342-52. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.